HEPA vs. ADTX, SRNE, KRBP, TFFP, TCBP, BON, HSTO, SMFL, NAVB, and SCPS
Should you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Aditxt (ADTX), Sorrento Therapeutics (SRNE), Kiromic BioPharma (KRBP), TFF Pharmaceuticals (TFFP), TC Biopharm (TCBP), Bon Natural Life (BON), Histogen (HSTO), Smart for Life (SMFL), Navidea Biopharmaceuticals (NAVB), and Scopus BioPharma (SCPS). These companies are all part of the "pharmaceutical products" industry.
Hepion Pharmaceuticals vs.
Aditxt (NASDAQ:ADTX) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
In the previous week, Aditxt had 5 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 7 mentions for Aditxt and 2 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.96 beat Aditxt's score of 0.29 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.
Aditxt has higher revenue and earnings than Hepion Pharmaceuticals.
Aditxt has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
Aditxt's return on equity of -439.07% beat Hepion Pharmaceuticals' return on equity.
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 4.7% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Hepion Pharmaceuticals received 17 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Summary
Hepion Pharmaceuticals beats Aditxt on 6 of the 11 factors compared between the two stocks.
Get Hepion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hepion Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:HEPA) was last updated on 3/29/2025 by MarketBeat.com Staff
